DNA polymerase delta 2, accessory subunitGenealiases: []
Q-omics provides the consensus-scored POLD2 profile across patient tissues and cancer cell-line models. POLD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, POLD2 is differentially expressed in 18, with the highest sampling consensus in KIRC. Additionally, POLD2 protein abundance shows 30,077 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where POLD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLD2 survival associations across molecular data types. POLD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLD2 RNA expression–survival associations across cancer types. High POLD2 expression shows unfavorable associations in MESO, KICH, LUAD, ACC and HNSC, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for POLD2 RNA expression.
This table summarizes POLD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLD2 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, KIRP, LUAD and BLCA. The KIRC box plot shows higher POLD2 RNA expression in tumor versus normal tissue (log2 FC = +0.801, t-test p < 0.001).
This table shows molecular features associated with POLD2 in patient tissues and cancer cell lines. In patient samples, POLD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
